SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
CytoMed Announces Collaboration with Singapore Sengkang General Hospital
Malaysian Patent Granted for CytoMed's Allogeneic Delta T Cell Technology
CytoMed Therapeutics Reports First Half 2023 Financial Report
Singapore based startup CytoMed Therapeutics, spun off from the Agency for Science, Technology and Research (A*STAR), has entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Center in Houston, Texas, US to use gamma-delta T cells (gdTc) for the treatment of acute myeloid leukaemia (AML) and breast cancer.